5-trifluoromethyl-4'-phenylsalicylanilide | 220340-69-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-trifluoromethyl-4'-phenylsalicylanilide
• 英文别名: 2-hydroxy-N-(4-phenylphenyl)-5-(trifluoromethyl)benzamide
• CAS: 220340-69-2
• 化学式: C₂₀H₁₄F₃NO₂
• 分子量: 357.332
• InChiKey: BHIZBPUQSWXTLH-UHFFFAOYSA-N

物化性质

• 沸点：
  428.9±45.0 °C(Predicted)
• 密度：
  1.345±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  26
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  4-三氟甲基水杨酸 、 4-氨基联苯 、 三氯化磷 以 氯苯 为溶剂， 生成 5-trifluoromethyl-4'-phenylsalicylanilide
  参考文献：
  名称：

  Macrophage scavenger receptor antagonists for use in the treatment of cardiovascular diseases

  摘要：

  提供了作为巨噬细胞清道夫受体拮抗剂的水杨酰苯胺衍生物。还提供了治疗心血管疾病的方法，包括给予目前的化合物。目前的化合物抑制了巨噬细胞来源的泡沫细胞内的脂质积累。

  公开号：

  US06255298B1

文献信息

• O-substituted hydroxyaryl derivatives
  申请人：Muto Susumu

  公开号：US20060094718A1

  公开（公告）日：2006-05-04

  A medicament having inhibitory activity against NF-κB activation which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein X represents a connecting group whose number of atoms in a main chain is 2 to 5 (said connecting group may be substituted), “A” represents an acyl group which may be substituted, (provided that unsubstituted acetyl group and unsubstituted acryloyl group are excluded,) or a C 1 to C 6 alkyl group which may be substituted, or A may bind to connecting group X to form a cyclic structure which may be substituted, “E” represents an aryl group which may be substituted or a heteroaryl group which may be substituted, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above.

  一种药物具有抑制NF-κB激活活性，其包括以下通式(I)所表示的化合物或其药学上可接受的盐、水合物或溶剂化物作为活性成分，其中X表示主链中原子数为2至5的连接基（该连接基可以被取代），A表示可以被取代的酰基（不包括未取代的乙酰基和未取代的丙烯酰基）或者可以被取代的C1到C6烷基，或者A可以与连接基X结合形成可以被取代的环状结构，E表示可以被取代的芳基或者可以被取代的杂环基，环Z表示可以具有一个或多个取代基的芳基（除了由式—O-A所表示的基团外，A具有与上述定义相同的含义，由式—X-E所表示的基团，X和E具有与上述定义相同的含义）或者可以具有一个或多个取代基的杂环基（除了由式—O-A所表示的基团外，A具有与上述定义相同的含义，由式—X-E所表示的基团，X和E具有与上述定义相同的含义）。
• Inhibitors against activation of NF-kappaB
  申请人：MUTO Susumu

  公开号：US20080311074A1

  公开（公告）日：2008-12-18

  A method of inhibiting NF-κB activation in a mammal including a human, which comprises the step of administering an effective dose of a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof:

  一种抑制哺乳动物（包括人类）中NF-κB激活的方法，包括以下步骤：给予所选物质的有效剂量，所选物质选自以下组合：一种由下列通式（I）表示的化合物及其药理学上可接受的盐、水合物和溶剂化物。
• O-SUBSTITUTED HYDROXYARYL DERIVATIVES
  申请人：Institute of Medicinal Molecular Design, Inc.

  公开号：EP1512397B1

  公开（公告）日：2014-10-08
• MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR DISEASES
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：EP1005347A1

  公开（公告）日：2000-06-07
• EP1005347A4
  申请人：——

  公开号：EP1005347A4

  公开（公告）日：2002-08-28